NCT02363452View on ClinicalTrials.gov

Reverse Transcriptase Inhibitors in AGS

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 10, 2015

Primary Completion Date

January 31, 2018

Study Completion Date

June 30, 2018

Conditions
Aicardi-Goutières Syndrome (AGS)
Interventions
DRUG

Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir

Oral Solution (syrup) or Tablets

Trial Locations (1)

75015

Hôpital Necker - Enfants Malades, Paris

All Listed Sponsors
collaborator

URC-CIC Paris Descartes Necker Cochin

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02363452 - Reverse Transcriptase Inhibitors in AGS | Biotech Hunter | Biotech Hunter